Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126278262 | 12627826 | 2 | F | 20160808 | 20160806 | 20160818 | EXP | US-TEVA-606741USA | TEVA | SAN GABRIEL ET AL M. | 42.00 | YR | M | Y | 0.00000 | 20160818 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126278262 | 12627826 | 1 | PS | OLANZAPINE. | OLANZAPINE | 1 | Unknown | 20 MG OF OLANZAPINE DAILY AT BEDTIME | Y | 76000 | 20 | MG | QD | ||||||
| 126278262 | 12627826 | 2 | SS | QUETIAPINE FUMARATE. | QUETIAPINE FUMARATE | 1 | Unknown | Y | 77745 | 50 | MG | ||||||||
| 126278262 | 12627826 | 3 | SS | QUETIAPINE FUMARATE. | QUETIAPINE FUMARATE | 1 | Unknown | SLOWLY UP-TITRATED 100 MG DAILY FOR NEXT 3 DAYS | Y | 77745 | 100 | MG | |||||||
| 126278262 | 12627826 | 4 | SS | CLOZAPINE. | CLOZAPINE | 1 | Unknown | Y | 74949 | 12.5 | MG | ||||||||
| 126278262 | 12627826 | 5 | SS | CLOZAPINE. | CLOZAPINE | 1 | Unknown | SLOWLY TITRATED TO 175 MILLIGRAMS OVER 20 DAYS | Y | 74949 | 175 | MG | |||||||
| 126278262 | 12627826 | 6 | SS | CLONAZEPAM. | CLONAZEPAM | 1 | Unknown | TWICE A DAY (BID) | Y | 74569 | .5 | MG | BID | ||||||
| 126278262 | 12627826 | 7 | SS | CLONAZEPAM. | CLONAZEPAM | 1 | Unknown | Y | 74569 | 1 | MG | TID | |||||||
| 126278262 | 12627826 | 8 | C | HALOPERIDOL. | HALOPERIDOL | 1 | Oral | Y | 0 | 5 | MG | ||||||||
| 126278262 | 12627826 | 9 | C | HALOPERIDOL. | HALOPERIDOL | 1 | Intramuscular | Y | 0 | 15 | MG | ||||||||
| 126278262 | 12627826 | 10 | C | LORAZEPAM. | LORAZEPAM | 1 | Oral | 0 | 2 | MG | |||||||||
| 126278262 | 12627826 | 11 | C | LORAZEPAM. | LORAZEPAM | 1 | Intramuscular | 0 | 5 | MG | |||||||||
| 126278262 | 12627826 | 12 | C | CHLORPROMAZINE. | CHLORPROMAZINE | 1 | Intramuscular | 0 | 100 | MG | |||||||||
| 126278262 | 12627826 | 13 | C | VALPROIC ACID. | VALPROIC ACID | 1 | Unknown | 500 MG AT BEDTIME | 0 | 500 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126278262 | 12627826 | 1 | Schizoaffective disorder |
| 126278262 | 12627826 | 2 | Schizoaffective disorder |
| 126278262 | 12627826 | 3 | Schizoaffective disorder |
| 126278262 | 12627826 | 4 | Schizoaffective disorder |
| 126278262 | 12627826 | 5 | Schizoaffective disorder |
| 126278262 | 12627826 | 6 | Schizoaffective disorder depressive type |
| 126278262 | 12627826 | 8 | Schizoaffective disorder |
| 126278262 | 12627826 | 9 | Schizoaffective disorder |
| 126278262 | 12627826 | 10 | Aggression |
| 126278262 | 12627826 | 12 | Schizoaffective disorder |
| 126278262 | 12627826 | 13 | Schizoaffective disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126278262 | 12627826 | OT |
| 126278262 | 12627826 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126278262 | 12627826 | Neuroleptic malignant syndrome | |
| 126278262 | 12627826 | Rhabdomyolysis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |